**Executive summary:** This week offered a study in contrasts for European technology. Venture investors committed well over €100 million to a trio of European startups applying AI and software infrastructure to healthcare and financial connectivity, while European tech equities slid to a six-week low after prominent AI executives publicly called for a slowdown in what they termed "reckless" development. The divergence is not a contradiction but a signal: capital is rotating away from undifferentiated exposure to the AI platform race and toward companies that embed intelligence into regulated, workflow-heavy industries where adoption is measurable and the moat is domain expertise rather than raw model capability. --- ## The Private Market Verdict: Vertical AI Is Where Europe Competes The largest European funding announcement of the week came from Stockholm. Tandem Health, which is building what it describes as a complete AI medical assistant for European clinics, raised €86.49 million ($100 million) in Series B funding, according to EU-Startups. The round was led by the Scaleup Europe Fund, managed by EQT, with participation from existing backers Kinnevik, Northzone, Amino Collective and Visionaries. Tandem had already announced a prior round in June 2025, meaning the company has returned to market for a substantially larger cheque within a matter of months. Several aspects of this deal merit attention. First, the lead investor. The Scaleup Europe Fund is precisely the type of vehicle European policymakers have long argued was missing from the continent's capital stack: a growth-stage fund with the capacity to write nine-figure cheques and keep promising companies from relocating to the United States at the point of scale. That its first major HealthTech commitment went to an "AI-native operating system for European healthcare," in EU-Startups' framing, tells us something about where large European growth investors believe the region can build defensible category leaders. Second, the framing itself. Tandem is not positioning as a general-purpose AI company. It is positioning as clinical infrastructure. The distinction matters because the economics of general-purpose model development have become punishing, dominated by a handful of hyperscalers with balance sheets no European startup can match. Clinical documentation, administrative workflow and decision support within fragmented national health systems, by contrast, reward local regulatory knowledge, language coverage and integration with legacy systems. These are areas where a Stockholm company can plausibly out-execute a Silicon Valley one. ## Consolidation Arrives Early in Preventive Health If Tandem represents the growth-stage thesis, Zurich-based Aeon illustrates how quickly consolidation is arriving at the seed stage. EU-Startups reported exclusively that Aeon, which is developing AI-powered whole-body health check-ups, has closed a Seed extension and simultaneously acquired Aware Health, a German blood diagnostics platform. The extension brings Aeon's total Seed funding to over €12 million ($14 million), building on an €8.2 million raise in June 2025. A seed-stage company making an acquisition is unusual and instructive. It suggests two things. The first is that Aeon's investors are willing to fund inorganic growth before the company has reached Series A, which reflects confidence in the management team's ability to integrate rather than merely build. The second is that the preventive health market in the German-speaking region is already fragmenting into complementary niches—diagnostics, imaging, longitudinal tracking—that are more valuable combined than separate. Aware Health's blood diagnostics capability gives Aeon a data layer that its whole-body scanning product would otherwise need years to develop organically. The pattern also mirrors the Tandem story in one important respect: both companies are building platforms whose value comes from aggregating multiple clinical data streams under a single AI-driven interface. Whether at €12 million or €86 million, the bet is the same. The winners in European HealthTech will be those who own the workflow, not those who own the model. ## Financial Plumbing Gets Its Own Layer The week's third notable deal was smaller but strategically coherent with the others. Chift, a Brussels-based startup, raised €10.5 million in Series A funding led by BlackFin Capital Partners, a specialist European FinTech investor managing more than €4 billion, per EU-Startups. Chift describes itself as a financial connectivity layer for European software—an integration platform that lets software vendors connect their products to the accounting, invoicing and payment tools their users already rely on. This is unglamorous infrastructure, and that is precisely the point. Europe's fragmentation across dozens of national accounting standards, invoicing regimes and banking APIs is a persistent tax on software companies attempting to scale across borders. A vendor that has built its product for the Belgian market must re-engineer integrations for France, Germany and the Netherlands. Chift's proposition is to absorb that complexity once and sell it many times over. The involvement of BlackFin is significant. Specialist FinTech investors with more than €4 billion under ma